Piper Sandler Maintains Overweight on Guardant Health, Raises Price Target to $34
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Westenberg maintains an Overweight rating on Guardant Health (NASDAQ:GH) and raises the price target from $30 to $34.
August 13, 2024 | 3:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler analyst David Westenberg maintains an Overweight rating on Guardant Health and raises the price target from $30 to $34.
The Overweight rating and increased price target from a reputable analyst at Piper Sandler is likely to positively influence investor sentiment and drive short-term price appreciation for Guardant Health.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100